Anti-tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs

Liver International

Volumn 25, Issue 2, 2005, Pages 410-419

  Torres Collado, Antoni Xavier ^a   Czaja, Albert J ^b   Gelpí, Carmen ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b MAYO CLINIC   (United States)

Author keywords

AIH, autoimmune hepatitis; Anti tRNP(Ser)Sec; Autoantibodies eukaryotically expressed antigen; LP; Prokaryotically expressed antigen; SLA; tRNA(Ser)Sec

Indexed keywords

AZATHIOPRINE; CELL EXTRACT; PREDNISONE; RECOMBINANT PROTEIN; RIBONUCLEOPROTEIN ANTIBODY; RNA;

ADULT; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOTE; FEMALE; HELA CELL; HEPATITIS C; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PROKARYOTE; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS, AUTOIMMUNE; HEPATITIS, CHRONIC; HUMANS; IMMUNOBLOTTING; MALE; PROBABILITY; RECOMBINANT PROTEINS; RIBONUCLEOPROTEINS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 17044383036     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01079.x     Document Type: Article

References (33)

1. Maddrey W C. Subdivisions of idiopathic autoimmune chronic active hepatitis. Hepatology 1987; 7: 1372-5.
2. Maddrey W C. Chronic hepatitis. Dis Mon 1993; 39: 53-125.
3. Obermayer-Straub P, Strassburg C P, Manns M P. Autoimmune hepatitis. J Hepatol 2000; 32(Suppl. 1): 181-97.
4. Czaja A J, Manns M P. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 1995; 90: 1206-11.
5. Gelpi C, Sontheimer J, Rodriguez-Sanchez J L. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA 1992; 89: 9739-43.
6. Czaja A J, Manns M P, Homburger H A. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290-5.
7. Bittencourt P L, Goldberg A C, Cancado E L, Porta G, Carrilho F J, Farias A Q, Palacios S A, Chiarella J M, Abrantes-Lemos C P, Babbio V L, Laudanna A A, Kalil J. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999; 94: 1906-13.
8. Czaja J, Doherty D G, Donaldson P T. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47: 2139-50.
9. Czaja A J, Donaldson P T, Lohse A W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-9.
10. Czaja A J. Autoimmune hepatitis. Evolving concepts and treatment strategies. Dig Dis Sci 1995; 40: 435-56.
11. Czaja A J. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394-401.
12. Ballot E, Bruneel A, Labas V, Johanet C. Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin Chem 2003; 49: 634-43.
13. Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde K H, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-5.
14. Costa M, Rodriguez-Sanchez J L, Czaja A J, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol 2000; 121: 364-74.
15. Volkmann M, Martin L, Baurle A, Heid H, Strassburg C P, Trautwein C, Fiehn W, Manns M P. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 2001; 33: 591-6.
16. Jung J E, Karoor V, Sandbaken M G, Lee B J, Ohama T, Gesteland R F, Atkins J F, Mullenbach G T, Hill K E, Wahba A J, et al. Utilization of selenocysteyl-tRNA[-Ser]Sec and seryl-tRNA[Ser]Sec in protein synthesis. J Biol Chem 1994; 269: 29739-45.
17. Bock A, Forchhammer K, Heider J, Baron C. Selenoprotein synthesis: an expansion of the genetic code. Trends Biochem Sci 1991; 16: 463-7.
18. Berry M J, Banu L, Chen Y Y, Mandel S J, Kieffer J D, Harney J W, Larsen P R. Recognition of UGA as a selenocysteine codon in type I deiodinase requires sequences in the 3′ untraslated region. Nature 1991; 353: 273-6.
19. Ding F, Grabowski P J. Identification of a protein component of a mammalian tRNA(Sec) complex implicated in the decoding of UGA as selenocysteine. RNA 1999; 5: 1561-9.
20. Shen Q, McQuilkin PA, Newburger P E. RNA-binding proteins that specifically recognize the selenocysteine insertion sequence of human cellular glutathione peroxidase mRNA. J Biol Chem 1995; 270: 30448-52.
21. Fagegaltier D, Hubert N, Carbon P, Krol A. The selenocysteine insertion sequence binding protein SBP is different from the Y-box protein dbpB. Biochimie 2000; 82: 117-22.
22. Copeland P R, Driscoll D M. Purification, redox sensitivity, and RNA binding properties of SECIS-binding protein 2, a protein involved in selenoprotein biosynthesis. J Biol Chem 1999; 274: 25447-54.
23. Tujebajeva R M, Copeland P R, Xu X-M, Carlson B A, Harney J W, Driscoll D M, Hatfield D L, Berry M J. Decoding apparatus for eukaryot selenocysteine insertion. EMBO Rep 2000; 1: 158-63.
24. Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.
25. Czaja A J, Cassani F, Cataleta M, Valentini P, Bianchi F B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068-73.
26. Czaja A J, Pfeifer K D, Decker R H, Vallari A S. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733-40.
27. Lerner M R, Steitz J A. Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1979; 76: 5495-9.
28. Baeres M, Herkel J, Czaja A J, Wies I, Kanzler S, Cancado E L, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle P R, Lohse A W. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-64.
29. Ma Y, Okamoto M, Thomas M G, Bogdanos D P, Lopes A R, Portmann B, Underhill J, Durr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.
30. Vitozzi S, Djilali-Saiah I, Lapierre P, Alvarez F. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 2002; 35: 485-92.
31. Manns M P. Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis. J Hepatol 2000; 33: 326-8.
32. Love L A, Leff R L, Fraser D D, Tragoff I N, Dalakas M, Plotz P H, Miller F W. A new approach to the classification in idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patients groups. Medicine (Balt) 1991; 70: 360-74.
33. Bogdanos D-P, Mieli-Vergani G. Targets of antibodies to soluble liver antigen in patients with autoimmune hepatitis. Clin Chem 2004; 50: 682-3.